⌕
Phathom Pharmaceuticals · PHAT · Nasdaq
Tenet 33 · Weak
Compare
$5.30−3.64%At closeTenet 33 · Weak
$5.30−0.20 (−3.64%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

Phathom Pharmaceuticals (PHAT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~1502.4%/yr (FY23→FY25), net margin −126.3%. Worth your attention in FY25: Share count (+97.1%) and Capex step-up ($229.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲216.9%
175.1
FY21→FY25CAGR —
Net income ($M)▲33.8%
−221.2
FY21→FY25CAGR —
Free cash flow ($M)▲37.4%
−167.0
capex stepped upCAGR —
Diluted EPS▲42.7%
−3.03
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+97.1%

37.0mn → 72.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$229.0K

▲70% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)175.1Revenue−22.6COGS152.5Gross profit−32.8R&D−279.7SG&A−160.0Op income−61.3Tax & other−221.2Net income

-126¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Net margin -126.3% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
274,881.0175,110.055,252.0682.00.00.0▲216.9%—
Cost of revenue
53,106.022,599.07,973.0167.00.00.0▲183.4%—
Gross profit
221,775.0152,511.047,279.0515.00.00.0▲222.6%—
Research & development
31,822.032,780.034,082.049,899.071,441.072,338.0▼3.8%−18.0%
Selling, general & admin
215,408.0279,717.0290,664.0117,928.0100,999.062,742.0▼3.8%+45.3%
Total operating expenses
247,230.0312,497.0324,746.0167,827.0172,440.0135,080.0▼3.8%+23.3%
Operating incomefeeds ROC rank
−25,455.0−159,986.0−277,467.0−167,312.0−172,440.0−135,080.0▲42.3%—
Other income, net
−57,541.0−61,261.0−56,859.0−34,280.0−25,283.0−8,803.0——
Pretax income
−82,996.0−221,247.0−334,326.0−201,592.0−197,723.0−143,883.0▲33.8%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−82,996.0−221,247.0−334,326.0−201,592.0−197,723.0−143,883.0▲33.8%—
Per share
Diluted EPSbuyback-sensitive
−1.00−3.03−5.29−3.93−5.05−3.89▲42.7%—
Diluted shares (mn)
84.8972.9263.1851.2939.1237.00▲15.4%+18.5%
Margins
Gross margin75th pct in Healthcare
80.7%87.1%85.6%75.5%——▲1.5pp+11.6pp
Operating margin
−9.3%−91.4%−502.2%−24532.6%——▲410.8pp+24441.2pp
Net margin19th pct in Healthcare
−30.2%−126.3%−605.1%−29558.9%——▲478.7pp+29432.6pp
† TTM = trailing four quarters through 2026-09-30.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Phathom Pharmaceuticals' revenue last fiscal year?

Phathom Pharmaceuticals reported revenue of $175.1M in fiscal 2025, up 216.9% from fiscal 2024.

What was Phathom Pharmaceuticals' net income?

Phathom Pharmaceuticals reported net income of −$221.2M in fiscal 2025, a net margin of −126.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.